Abstract
Sphingomyelinases are a group of hydrolases that cleave sphingomyelin, a common component of plasma membranes, to form ceramide and phosphocholine. Ceramide is a second messenger that is present in virtually all cell types and regulates a variety of cellular functions such as proliferation, differentiation, apoptosis, and inflammation response. Inhibition of sphingomyelinase activity to reduce ceramide concentrations has recently emerged as a potential therapeutic approach for several diseases including atherosclerosis, pathogen infections, inflammation, diabetes, and obesity. To effectively screen compound collections for the identification of new sphingomyelinase inhibitors, we have developed a high-throughput assay utilizing the natural substrate sphingomyelin in 1,536-well plate format. The assay has a signal-to-basal ratio of 6.1-fold in pH 5.0 buffer and 4.3-fold in pH 6.5 buffer, indicating a robust assay for compound library screening. A screen of ~300,000 compounds using this assay led to the identification of eight compounds as sphingomyelinase inhibitors (IC50s = 1.7 to 38.2 μM) that exhibited different activities between the natural substrate assay and profluorescence substrate assay. The results demonstrate the robustness and effectiveness of the natural substrate sphingomyelinase assay for screening sphingomyelinase inhibitors.
Similar content being viewed by others
References
Pavoine C, Pecker F (2009) Sphingomyelinases: their regulation and roles in cardiovascular pathophysiology. Cardiovasc Res 82(2):175–183
Schuchman EH (2010) Acid sphingomyelinase, cell membranes and human disease: lessons from Niemann-Pick disease. FEBS Lett 584(9):1895–1900
Schissel SL, Schuchman EH, Williams KJ, Tabas I (1996) Zn2+-stimulated sphingomyelinase is secreted by many cell types and is a product of the acid sphingomyelinase gene. J Biol Chem 271(31):18431–18436
Schuchman EH, Suchi M, Takahashi T, Sandhoff K, Desnick RJ (1991) Human acid sphingomyelinase. Isolation, nucleotide sequence and expression of the full-length and alternatively spliced cDNAs. J Biol Chem 266(13):8531–8539
Hofmann K, Tomiuk S, Wolff G, Stoffel W (2000) Cloning and characterization of the mammalian brain-specific, Mg2 + -dependent neutral sphingomyelinase. Proc Natl Acad Sci USA 97(11):5895–5900
Krut O, Wiegmann K, Kashkar H, Yazdanpanah B, Kronke M (2006) Novel tumor necrosis factor-responsive mammalian neutral sphingomyelinase-3 is a C-tail-anchored protein. J Biol Chem 281(19):13784–13793
Tomiuk S, Hofmann K, Nix M, Zumbansen M, Stoffel W (1998) Cloned mammalian neutral sphingomyelinase: functions in sphingolipid signaling? Proc Natl Acad Sci USA 95(7):3638–3643
Lang F, Ullrich S, Gulbins E (2011) Ceramide formation as a target in beta-cell survival and function. Expert Opin Ther Targets 15(9):1061–1071
Truman JP, Al Gadban MM, Smith KJ, Hammad SM (2011) Acid sphingomyelinase in macrophage biology. Cell Mol Life Sci 68(20):3293–3305
Zeidan YH, Hannun YA (2010) The acid sphingomyelinase/ceramide pathway: biomedical significance and mechanisms of regulation. Curr Mol Med 10(5):454–466
Jenkins RW, Canals D, Hannun YA (2009) Roles and regulation of secretory and lysosomal acid sphingomyelinase. Cell Signal 21(6):836–846
Becker KA, Riethmuller J, Luth A, Doring G, Kleuser B, Gulbins E (2010) Acid sphingomyelinase inhibitors normalize pulmonary ceramide and inflammation in cystic fibrosis. Am J Respir Cell Mol Biol 42(6):716–724
Goggel R, Winoto-Morbach S, Vielhaber G, Imai Y, Lindner K, Brade L, Brade H, Ehlers S, Slutsky AS, Schutze S, Gulbins E, Uhlig S (2004) PAF-mediated pulmonary edema: a new role for acid sphingomyelinase and ceramide. Nat Med 10(2):155–160
Boini KM, Zhang C, Xia M, Poklis JL, Li PL (2010) Role of sphingolipid mediator ceramide in obesity and renal injury in mice fed a high-fat diet. J Pharmacol Exp Ther 334(3):839–846
Samad F, Badeanlou L, Shah C, Yang G (2011) Adipose tissue and ceramide biosynthesis in the pathogenesis of obesity. Adv Exp Med Biol 721:67–86
Schmitz-Peiffer C (2010) Targeting ceramide synthesis to reverse insulin resistance. Diabetes 59(10):2351–2353
Grassme H, Gulbins E, Brenner B, Ferlinz K, Sandhoff K, Harzer K, Lang F, Meyer TF (1997) Acidic sphingomyelinase mediates entry of N. gonorrhoeae into nonphagocytic cells. Cell 91(5):605–615
Hauck CR, Grassme H, Bock J, Jendrossek V, Ferlinz K, Meyer TF, Gulbins E (2000) Acid sphingomyelinase is involved in CEACAM receptor-mediated phagocytosis of Neisseria gonorrhoeae. FEBS Lett 478(3):260–266
Arenz C (2010) Small molecule inhibitors of acid sphingomyelinase. Cellular physiology and biochemistry. Int J Exp Cell Phys, Biochem, and Pharmacol 26(1):1-8
Kornhuber J, Tripal P, Reichel M, Muhle C, Rhein C, Muehlbacher M, Groemer TW, Gulbins E (2010) Functional inhibitors of acid sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications. Cell Physiol Biochem 26(1):9–20
Duan RD, Nilsson A (2000) Sphingolipid hydrolyzing enzymes in the gastrointestinal tract. Methods Enzymol 311:276–286
Liu F, Cheng Y, Wu J, Tauschel HD, Duan RD (2006) Ursodeoxycholic acid differentially affects three types of sphingomyelinase in human colon cancer Caco 2 cells. Cancer Lett 235(1):141–146
Loidl A, Claus R, Deigner HP, Hermetter A (2002) High-precision fluorescence assay for sphingomyelinase activity of isolated enzymes and cell lysates. J Lipid Res 43(5):815–823
Mintzer RJ, Appell KC, Cole A, Johns A, Pagila R, Polokoff MA, Tabas I, Snider RM, Meurer-Ogden JA (2005) A novel high-throughput screening format to identify inhibitors of secreted acid sphingomyelinase. J Biomol Screen 10(3):225–234
van Diggelen OP, Voznyi YV, Keulemans JL, Schoonderwoerd K, Ledvinova J, Mengel E, Zschiesche M, Santer R, Harzer K (2005) A new fluorimetric enzyme assay for the diagnosis of Niemann-Pick A/B, with specificity of natural sphingomyelinase substrate. J Inherit Metab Dis 28(5):733–741
Shi ZD, Motabar O, Goldin E, Liu K, Southall N, Sidransky E, Austin CP, Griffiths GL, Zheng W (2009) Synthesis and characterization of a new fluorogenic substrate for alpha-galactosidase. Anal Bioanal Chem 394(7):1903–1909
Motabar O, Shi ZD, Goldin E, Liu K, Southall N, Sidransky E, Austin CP, Griffiths GL, Zheng W (2009) A new resorufin-based alpha-glucosidase assay for high-throughput screening. Anal Biochem 390(1):79–84
Goldin E, Zheng W, Motabar O, Southall N, Choi JH, Marugan J, Austin CP, Sidransky E (2012) High throughput screening for small molecule therapy for Gaucher disease using patient tissue as the source of mutant glucocerebrosidase. PLoS One 7(1):e29861
Motabar O, Goldin E, Leister W, Liu K, Southall N, Huang W, Marugan JJ, Sidransky E, Zheng W (2012) A high throughput glucocerebrosidase assay using the natural substrate glucosylceramide. Anal Bioanal Chem 402(2):731–739
Lansmann S, Ferlinz K, Hurwitz R, Bartelsen O, Glombitza G, Sandhoff K (1996) Purification of acid sphingomyelinase from human placenta: characterization and N-terminal sequence. FEBS Lett 399(3):227–231
Acknowledgments
The authors thank Sam Michael for assistance in robotic screen, Paul Shinn for assistance in compound management, and Seameen J. Dehdashti for critical reading of the manuscript. The authors also thank ATT Bioquest for technical assistance on the assay development and optimization. This research was supported by the Molecular Libraries Initiative of the NIH Roadmap for Medical Research (5U54MH084681-02 and RO3MH093173-01) and the Intramural Research Programs of National Heart, Lung and Blood Institute, National Institutes of Health.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Xu, M., Liu, K., Southall, N. et al. A high-throughput sphingomyelinase assay using natural substrate. Anal Bioanal Chem 404, 407–414 (2012). https://doi.org/10.1007/s00216-012-6174-5
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00216-012-6174-5